Ionis Pharmaceuticals
Coverage of Ionis Pharmaceuticals in the Nexus archive.
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.
- Experimental hepatitis B drug may offer ‘functional cure’ for some patients
An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.